Comparative Pharmacology
Head-to-head clinical analysis: KANAMYCIN SULFATE versus ZINC BACITRACIN NEOMYCIN SULFATE POLYMYXIN B SULFATE HYDROCORTISONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KANAMYCIN SULFATE versus ZINC BACITRACIN NEOMYCIN SULFATE POLYMYXIN B SULFATE HYDROCORTISONE.
KANAMYCIN SULFATE vs ZINC BACITRACIN,NEOMYCIN SULFATE,POLYMYXIN B SULFATE & HYDROCORTISONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminoglycoside antibiotic that irreversibly binds to the 30S ribosomal subunit, inhibiting protein synthesis and causing mRNA misreading.
Combination antibiotic and corticosteroid: Neomycin, polymyxin B, and bacitracin are antibiotics that inhibit bacterial protein synthesis, disrupt cell membrane permeability, and inhibit cell wall synthesis, respectively; hydrocortisone is a corticosteroid that suppresses inflammatory responses by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis.
15 mg/kg/day IM or IV divided every 8-12 hours; typical adult dose: 500 mg IM every 12 hours or 7.5 mg/kg every 12 hours. Maximum total daily dose: 1.5 g.
Apply 3-4 times daily to affected area as a thin layer. Topical route. Frequency: every 6-12 hours.
None Documented
None Documented
Terminal elimination half-life is 2-4 hours in adults with normal renal function; prolonged to 30-60 hours in severe renal impairment (CrCl <10 mL/min).
Neomycin: 2-3h (systemic, IM); Bacitracin: 1.5h (systemic, IM); Polymyxin B: 6h (systemic, IV); Hydrocortisone: 1.5-2h (systemic). Topical: not applicable due to minimal absorption.
Renal excretion of unchanged drug accounts for 80-90% of elimination; minor biliary excretion (<1%) and fecal elimination (<1%).
Renal: Neomycin (<1% absorbed, remainder fecal), Bacitracin (10-40% renal if absorbed, negligible), Polymyxin B (60% renal over 24h if absorbed), Hydrocortisone (metabolized, <1% unchanged renal; fecal for unabsorbed). Topical: negligible systemic absorption; fecal for unabsorbed.
Category C
Category A/B
Aminoglycoside Antibiotic
Aminoglycoside Antibiotic